Skip to content
10-Q

Quarterly Report

NKGen Biotech, Inc.

0001845459-26-000003

← back to feed
Filed
Jan 20, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Jan 16, 2026 130.6M sh
Shares Diluted Q1 2025 · Mar 31, 2025 102.65M sh
Shares Diluted Q1 2025 · Mar 31, 2024 21.94M sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$2.8M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$4.03M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $6K
Cash And Equivalents Q1 2025 · Dec 31, 2024 $106K
Stockholders Equity Q1 2025 · Mar 31, 2025 −$50.33M
Stockholders Equity Q1 2025 · Dec 31, 2024 −$69.91M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$55.06M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$58.69M
Current Liabilities Q1 2025 · Mar 31, 2025 $43.89M
Current Liabilities Q1 2025 · Dec 31, 2024 $57.97M
Total Liabilities Q1 2025 · Mar 31, 2025 $66.17M
Total Liabilities Q1 2025 · Dec 31, 2024 $86.14M
Current Assets Q1 2025 · Mar 31, 2025 $2.38M
Current Assets Q1 2025 · Dec 31, 2024 $2.46M
Total Assets Q1 2025 · Mar 31, 2025 $15.84M
Total Assets Q1 2025 · Dec 31, 2024 $16.23M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.04
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.25
Eps Basic Q1 2025 · Mar 31, 2025 $0.33
Eps Basic Q1 2025 · Mar 31, 2024 −$0.25
Rd Expense Q1 2025 · Mar 31, 2025 $1.86M
Rd Expense Q1 2025 · Mar 31, 2024 $3.24M
Net Income Q1 2025 · Mar 31, 2025 $15.35M
Net Income Q1 2025 · Mar 31, 2024 −$5.38M
Operating Income Q1 2025 · Mar 31, 2025 −$4.67M
Operating Income Q1 2025 · Mar 31, 2024 −$7.62M